HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1 Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2023 to Q4 2025

Type / Class
Debt / NOTE 1.000% 8/1
Market price (% of par)
132.79%
All holders as of 31 Dec 2025
Q4 2025
Total 13F principal
$429,219,360
Total reported market value
$570,586,563
Principal change
-$223,265,100
Market value change
-$306,242,660
Number of holders
53
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

As of 31 Dec 2025, 53 institutional investors reported holding $429,219,360 in principal (par value) of HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1.

Institutional Holders of HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1 across Reporting Periods

Period Principal Value Change Price (% of par) (Median) Investors
2025 Q4 $429,219,360 $570,586,563 -$306,242,660 132.79% 53
2025 Q3 $655,325,460 $920,432,391 +$102,237,538 140.75% 63
2025 Q2 $628,830,300 $718,645,608 -$27,561,128 114.08% 74
2025 Q1 $647,508,446 $828,761,473 +$4,645,168 128.11% 77
2024 Q4 $672,476,260 $730,001,496 -$62,779,579 108.09% 77
2024 Q3 $680,559,400 $810,707,471 +$105,250,543 118.98% 75
2024 Q2 $23,972,237,400 $717,063,397 -$3,930,381 111.16% 72
2024 Q1 $623,774,400 $607,993,350 -$28,940,823 97.4% 70
2023 Q4 $658,912,150 $616,721,993 -$3,988,874 93.09% 72
2023 Q3 $660,082,850 $622,263,753 +$620,529,779 93.71% 64